NIH is taking an all-hands-on-deck approach to speeding life-saving research for vaccines, treatments, and diagnostic tests to end the COVID-19 pandemic. Through the establishment of major public-private initiatives such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) and the Rapid Acceleration of Diagostics (RADx) initiatives, NIH and its partners have launched dozens of COVID-19 vaccine and treatment clinical trials and funded dozens of new and innovative testing technologies at an unprecedented rate.
To maintain this record pace, it will be crucial for clinical researchers involved in COVID-19 and SARS-CoV-2 clinical trials to share their results as swiftly as possible. Toward this end, I strongly encourage the clinical research community to register their clinical trials and submit summary results information for COVID-19 and SARS-CoV-2 trials as quickly as possible and ahead of regulatory and policy deadline requirements to ClinicalTrials.gov, the publicly accessible database operated by NIH’s National Library of Medicine.
To ensure such information is accessible as quickly as possible, NIH is prioritizing the processing of COVID-19 submissions to ClinicalTrials.gov to make the information rapidly available in a matter of days, not weeks. We are also providing one-on-one support to researchers during the process of submitting results information to ClinicalTrials.gov to address questions and optimize reporting.
NIH has taken several additional actions to speed access and discoverability for researchers, clinicians, and the public of critical information from COVID-19 and SARS-CoV-2 research, including:
The scientific community bears collective responsibility for expediting the dissemination of knowledge from NIH-funded research. Doing so will bring COVID-19 treatments and vaccines to the American public and the world as quickly as possible.
Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health